Malignant Bladder Neoplasm — Trials

Malignant Bladder Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 177
Ph III recruiting: 23
Growth YoY: +17.9%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.3%
Trials / 1,000 deaths: 20 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (179)

clinicaltrialsPublishedShowing 51–75 of 75 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01331824	Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma	terminated	Phase 2	22	Matthew GalskyOTHER	1	Apr 23, 2018	clinicaltrials
NCT00003452	Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder	terminated	Phase 2	4	Burzynski Research InstituteOTHER	1	Sep 28, 2017	clinicaltrials